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ABSTRACT
Nuclear factor TDP-43 is known to play an impor-
tant role in several neurodegenerative pathologies.
In general, TDP-43 is an abundant protein within the
eukaryotic nucleus that binds to many coding and
non-coding RNAs and influence their processing.
Using Drosophila, we have performed a functional
screening to establish the ability of major hnRNP
proteins to affect TDP-43 overexpression/depletion
phenotypes. Interestingly, we observed that lower-
ing hnRNP and TDP-43 expression has a generally
harmful effect on flies locomotor abilities. In parallel,
our study has also identified a distinct set of hnRNPs
that is capable of powerfully rescuing TDP-43 toxic-
ity in the fly eye (Hrb27c, CG42458, Glo and Syp).
Most importantly, removing the human orthologs of
Hrb27c (DAZAP1) in human neuronal cell lines can
correct several pre-mRNA splicing events altered by
TDP-43 depletion. Moreover, using RNA sequenc-
ing analysis we show that DAZAP1 and TDP-43 can
co-regulate an extensive number of biological pro-
cesses and molecular functions potentially impor-
tant for the neuron/motor neuron pathophysiology.
Our results suggest that changes in hnRNP expres-
sion levels can significantly modulate TDP-43 func-
tions and affect pathological outcomes.
INTRODUCTION
Recent experimental advances have highlighted that alter-
ations in RNA metabolism are very common in neurode-
generative diseases (1–4). From amechanistic point of view,
at the base of these alterations there is often the dysfunction
of one or several RNA binding proteins that play an impor-
tant role in regulating the functioning of neurons, especially
at the synaptic level (5,6).
For this reason, the identification of proteins and events
potentially altered during the course of disease might repre-
sent a critical step for outlining novel therapeutic strategies
to delay disease onset and/or progression. Unfortunately,
this is not an easy task because nuclear factors seldomwork
alone in determining the processing and ultimate fate of a
transcribed RNAs. In fact, most of them work via a com-
plex network of interactions with other factors which can
contribute to modify their functional properties in a cell- or
developmental-specific manner (7).
In this respect, TDP-43, as one of the major hnRNP pro-
tein involved in Amyotrophic Lateral Sclerosis (ALS) and
Frontotemporal Dementia (FTD) (8,9), is no exception to
this rule. In recent years, several high-throughput studies
performed on samples from human ALS/FTD patients or
in TDP-43 animal and cellular disease models have uncov-
ered a huge number of RNA processing events possibly dys-
regulated during disease (10–16).
In parallel with this huge number of potential targets,
proteomic analyses have identified more than 100 factors
that can bind to TDP-43 and potentially modify its actions
(17–20). Even a more selected estimate obtained on the ba-
sis of functional co-immunoprecipitation studies still yields
more than 20 interactions that can modify the biological
properties of TDP-43 (21).
In particular, hnRNP A/B family members represent
one of the key functional interactors of TDP-43 (22) and
can play an autonomous role in neurodegeneration. Muta-
tions in these proteins have been found to be independently
involved in causing ALS and multisystem proteinopathy
(23), whilst ALS-linked mutations in the Ubiquilin-2 gene
have been shown to abolish interaction of this factor with
hnRNP A1, A3 and U (24). Moreover, a cholinergic-
associated loss of hnRNP A/B expression has been found
associated with Alzheimer Disease (25) and a loss in hn-
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RNP A1 expression has been reported in ALS spinal cord
motoneurons carrying TDP-43 inclusions (26). Regarding
hnRNP proteins and ALS, it is also important to mention
the possible role played by hnRNP A3 and especially H/F
proteins binding to the G4C2 expansions of the C9orf72
region (27–31). Of interest, there is also the observation
that the interaction between TDP-43 and hnRNP proteins
is highly conserved throughout evolution. For example,
the Drosophila homolog of TDP-43 (TBPH) being capa-
ble of recognizing human hnRNP A/B proteins and vice
versa (32). Furthermore, the importance of this interac-
tion for the pathology has also been recently highlighted
by reports showing that overexpression of hnRNP U and
hnRNP A1/A2 can inhibit TDP-43-induced neuronal cell
death in NSC34 cells (33). Similarly, inDrosophila, the abil-
ity of TDP-43 to suppress CGGRNA-Fragile X-associated
tremor/ataxia syndrome associated phenotypes relies on
the interplay of this factor with two fly homologs of hn-
RNP A2/B1, whose overexpression could attenuate TDP-
43-toxicity (32–34). Also in Drosophila, it has been found
that the fly ortholog of human DAZAP1 can act as a domi-
nant modifier of a Valosin-containing protein (VCP) muta-
tion causing neurodegeneration, at least partly, because of
a toxic gain-of-function of TDP-43 redistribution from the
nucleus to the cytoplasm (35). Finally, we have also recently
reported that elevated human hnRNP levels in the brain of
FTLD-TDP patients may represent a defensemechanism in
repressing the inclusion of a TDP43-controlled, toxic exon,
within the Sort1 gene (36).
Therefore, a growing body of evidence suggests that vari-
ation in expression of different hnRNP proteins may rep-
resent a general response against TDP-43 gain- and loss-
of-function pathological effects, either by binding directly
to TDP-43 or by acting through common targets. To test
this hypothesis in a systematic manner, we have utilized
the evolutionary conserved hnRNPs present in Drosophila
melanogaster that may be considered one of the best model
systems nowadays available for the study of TDP-43 biol-
ogy andALS pathology (37,38). Our results suggest that the
majority of hnRNP proteins within the nucleus can affect
TDP-43 functionality both in loss-of-function and gain-of-
function disease models. Importantly, the ability by these
hnRNPs to modify fly phenotypes can also be observed in
their human homologs with regards to TDP43-controlled
events, especially at the pre-mRNA splicing level.
MATERIALS AND METHODS
Fly strains and maintenance
The complete genotype of the fly stocks are indicated below:
W1118, w; GMR-Gal4, w; GMR-Gal4, UAS-TBPH,
yw; UAS-mCD8::GFP, w; Elav-Gal4; UAS-Dicer-2, Elav-
Gal4, tbph23; UAS-TBPHRNAi/UAS-Dicer-2. The RNA
interference (RNAi) strains were obtained from Vienna
DrosophilaResource Center (VDRC)Drosophila stock cen-
tre and Bloomington Stock Center. All stocks and crosses
were maintained at 25◦C on a 12:12 h light:dark cycle, at
constant humidity on standard cornmeal medium.
Eye phenotype and examination
Eyes morphology of 1 day post-eclosion flies were exam-
ined and given points were scored for the presence of loss of
pigmentation, presence of neuronal death (black spot), reti-
nal collapse and ommatidial fusion. Points were assigned
on the following scale: one point was given each pheno-
type present, two points were given if the affected area was
more than 5%, three points were given if the compromised
area was more than 30% and four points were given if the
affected area was more than 65%. Additional two points
could be given for the presence of a high number of black
spots. For each genotype over 100 eyes were examined.
Climbing assay
To assess the negative geotaxis movement in adult flies, we
followed the previously established protocol (32). Shortly,
groups of 20 aged flies were transferred to the bottom of
a 50-ml cylinder without anaesthesia. After 30 s of adap-
tation, climbing ability was measured by counting the flies
that reached the top of the cylinder (10 cm) in 15 s. The ex-
periments were performed at 25◦C.
Western blotting in flies
Total proteins extract were obtained from adult heads.
The material has been squeezed in lysis buffer 1× (Lysis
buffer composition 1.5×: 225 mM NaCl, 15 mM Tris, 7.5
mM ethylenediaminetetraacetic acid (EDTA), 15% glycerol,
7.5mM ethylene glycol-bis(-aminoethyl ether)-N,N,N’,N’-
tetraacetic acid (EGTA), 75 mM NaF, 6 M urea, 7.5 mM
Dithiothreitol (DTT) and protease inhibitor) and then clar-
ified by a short centrifugation at 0.5 × g. The proteins were
separated by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and blotted on 0.2 m nitro-
cellulose membrane (Whatman Protran). Membranes were
blocked overnight in 5% non-fat dried milk in Tris-buffered
saline (TBS)-0.01% Tween 20 and probed with anti-Flag
M5 (Sigma, 1:10 000). Anti-Actin (Sigma1:5000) was used
as a total protein loading control. Proteins were detected
with Femto SuperSignal substrate (Thermo Scientific).
Gene knockdown
Human neuroblastoma SH-SY-5Y cells were cultured in
Dulbecco’s modified Eagle’s medium–Glutamax-I (Gibco-
BRL, Life Technologies Inc., Frederick, MD, USA)
supplemented with 10% fetal bovine serum (Gibco-
BRL, Life Technologies Inc., Frederick, MD, USA)
and Antibiotic-Antimycotic-stabilized suspension (Sig-
maAldrich, St Louis, MO, USA) at 37◦C incubator with
humidified atmosphere of 5% CO2. The siRNA sense se-
quences used for silencing the different target proteins
were the following: luciferase (control): uaaggcuaugaaga-
gauac, TDP-43: gcaaagccaagaugagccu, DAZAP1: gagacu-
cugcgcagcuacu, hnRNP Q/Syncrip: agacagugaucucucu-
cau, hnRNP R cauuugggaucuacgucuu. After twice gene si-
lencing byHyperfectamine (Qiagen Inc,Gaithersburg,MD,
USA), cells were collected and divided into two aliquots;
one-half for western blot and the other half for reverse
transcriptase-polymerase chain reaction (RT-PCR) analy-
sis.
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Western blotting
Total protein extracts were obtained by cell sonication in ly-
sis buffer composed of 1× phosphate buffered saline (PBS)
and 1× Complete Protease Inhibitor Cocktail (Roche Di-
agnostics, Mannheim, Germany). Proteins extract (20 g)
from each sample was loaded on a 10% SDS-PAGE. The gel
was then electroblotted onto aNitrocellulose blottingmem-
brane according to standard protocols (Amersham Bio-
sciences, Uppsala, Sweden) and blocked with 5% skimmed
milk (non-fat dry milk in 1× PBS and 0.1% Tween-20).
Proteins were probed with antibodies in order to con-
firm the gene knockdown efficacy and detected with en-
hanced chemiluminescence (ECL) Western Blotting Sub-
strate (Thermo Scientific, Rockford, IL, USA). Tubulin,
available in-house, was used as total protein loading con-
trol.
RNA extraction and RT-PCR analysis
RNA was obtained using Eurogold Trifast (Euroclone,
Milan, Italy), following the manufacturer’s instruc-
tions. One microgram of total RNA was used in the
retrotranscription reaction with random primers and
Moloney murine leukemia virus (M-MLV) Reverse
Transcriptase (Gibco-BRL, Life Technologies Inc., Fred-
erick, MD, USA). The primers for the target genes are
including: POLDIP3 Fw 5′-gcttaatgccagaccgggagttg-
3′; POLDIP3 Rv 5′-tcatcttcatccaggtcatataaatt-3′;
TNIK Fw 5′-caaaggcgagagaaggagctg-3′; TNIK
Rv 5′-ctgatgctgaagggaaactaag-3′; STAG2 Fw
5′-gtatgtttacttggaaaagttcatg-3′; STAG2 Rv 5′-
tgattcatccataattgaagctgga-3′; MADD Fw 5′-
gacctgaattgggtggcgagttccct-3′; MADD Rv 5′-
cattggtgtcttgtacttgtggctc-3′. PCR conditions for POLDIP3
and TNIK: 94◦C for 2 min, 94◦C for 30 s, 56◦C for 1
min and 72◦C for 45 s for 35 cycles; and 72◦C for 10 min
for the final extension. PCR conditions for STAG2 and
MADD: 94◦C for 2 min, 94◦C for 30 s, 50◦C for 30s and
72◦C for 1 min for 35 cycles; and 72◦C for 10 min for
the final extension. PCRs were optimized to be in the
exponential phase of amplification and products were
routinely fractionated in 1.5% (wt/vol) agarose gels. After
quantifications by densitometric analysis using ImageJ
software, the statistical significance was calculated using
unpaired t-test. P < 0.05 was considered significant (n = 3)
(*P < 0.05, **P < 0.01 and ***P < 0.001).
TDP-43 and DAZAP1 co-immunoprecipitations
HeLa cells (70% of confluence) were transfected with 3 g
of pFLAG-TDP-43 wild-type using the Effectene reagent.
After 24 h, cell culture medium was removed and cells were
washed with cold PBS and harvested. Cells were lysed in
500 l of IP buffer (20 mM Tris pH 7.5, 110 mM NaCl,
0.5% Triton-X, 1× Complete Protease Inhibitor Cocktail)
by sonication (3 min, mid power), in ice-cooled sonicat-
ing bath (BioRuptor, Diagenode, Belgium). The cell lysate
was pre-cleared by incubation with 30 l Protein A/G
PLUS agarose beads (Santa Cruz Biotechnology Inc., Dal-
las, Texas, USA) in IP buffer for 1.5 h at 4◦C. The pel-
lets were discarded and the supernatants were used for im-
munoprecipitation: the cell lysates were incubated with 2
g of mouse monoclonal anti-FLAGM2 antibody (Sigma-
Aldrich) on a rotating device for an hour at 4◦C. Then,
30 l of Protein A/G PLUS agarose beads were added to
each sample and incubated overnight at 4◦C. The pellet was
then washed three times in ice-cold IP buffer. The super-
natants was discarded, and the pellet was re-suspended in
30 l of 3× sample loading dye. The samples were fraction-
ated by SDS-PAGE (10%) and analyzed by immunoblot-
ting 1:2000 rabbit polyclonal anti-TDP-43 antibody (Pro-
teinTech), with 1:500 rabbit polyclonal anti-DAZAP1 anti-
body and 1:500 rabbit polyclonal anti-hnRNP H antibody
previously described (39,40).
RNA immunoprecipitation and RT-PCR analysis
Twenty-four hours after transfectin of 3 g flag-DAZAP1
by Effectene, HeLa cells were collected using HEGN buffer
(20 mMHepes pH 7.7, 150 mMNaCl, 0.5 mMEDTA, 10%
Glycerol, 0.1%TritonX-100, 1 mMDTT) and sonicated af-
ter adding protease inhibitory cocktail (Roche).HeLa lysate
(40 g) was incubated for 1 h at 4◦C in HEGN buffer
together with Protein A/G Agarose beads (Santa Cruz
Biotechnology Inc., Dallas, TX, USA), pre-coated with 5
g of anti-Flag antibody from Sigma, (IP-Flag) or with
uncoated beads as controls (IP-Beads). After washes with
HEGN + DOC 0.2% + Urea 0.5M, mRNA was phenol–
chloroform extracted from immunoprecipitated RNPs. The
abundance of possible DAZAP1 target genes was measured
by quantitative real-time PCR, using a Biorad Real-Time
PCR System and SYBR Green I Master (Roche), as de-
scribed below.
RNA sequencing and functional analysis of differentially ex-
pressed genes
Total RNA was extracted from TDP-43 and DAZAP1 de-
pleted SH-SY-5Y cells as described. As control, we used
total RNA extracted from SH-SY-5Y cells treated with
siRNA against luciferase. RNA sequencing was performed
at Eurofins (www.eurofins.com) using an Illumina HiSeq
2500 machine.
Data processing was carried out with HiSeq Con-
trol Software v2.0.12.0, Basecalls performed with RTA
v1.17.21.3. Reads were aligned to the human reference
(GRCh38) using BWA-MEM (bwa-0.7.12) with standard
parameters. Only uniquely aligned reads were used for ex-
pression profiling. Gene expression was measured based on
annotationGRCh38.ensembl genes 77 all exons using fea-
ture Counts (Subread package 1.4.6).
Raw read counts were converted to Counts per million
(CPM) values using Trimmed mean of M-values (TMM)
normalization (edgeR package). Differential expression
analysis was performed using the edgeR package. Features
had to have a counts-per-million value of more than one
in at least three samples or were removed. The interpreta-
tion of the differential expression genes data and pathway
mapping were performed by using the PANTHER (Pro-
tein ANalysis THrough Evolutionary Relationships) Clas-
sification System (41), the Database for Annotation, Visu-
alization and Integrated Discovery (DAVID) v6.7 (42) and
UniProt (43) tools.
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The statistical significance of the overlap between genes
regulated by TDP-43 (siTDP-43) and those regulated by
DAZAP1 (siDAZAP1) was evaluated by calculating the
representation factor and associated probability (hyperge-
ometric distribution test) as implemented in http://nemates.
org/MA/progs/overlap stats.html (44). The overlap was vi-
sualized with Venn diagrams using http://www.pangloss.
com/seidel/Protocols/venn.cgi.
Accession numbers
The data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus (45) and are acces-
sible through GEO Series accession number GSE97262
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE97262).
Quantitative real-time PCR analysis
Total RNA was extracted from SH-SY5Y cells transfected
with siRNA against TDP-43, DAZAP1, hnRNP Q and hn-
RNP R or co-transfected with siRNA against TDP-43 in
the presence of siRNA against each of the three tested hn-
RNPs. RNA obtained from SH-SY5Y cells treated with
siRNA against luciferase was used as negative control. For
eachRNA samples RT-PCRwas performed in order to syn-
thetize cDNA. The quantification of gene expression levels
was carried out by real-time PCR, using SYBR green tech-
nology. The gene-specific PCR primer pairs used are as fol-
lows: MADD, forward 5′-ttgagaccaactctgccaca-3′, reverse
5′-agactcgctggctcacatct-3′; BRD8, forward 5′-gcagcctgtta
cagatgac-3′, reverse 5′-aatagttgacaaatccataggc-3′; TNIK,
forward 5′-tggaacatacgggcaagttt-3′, reverse 5′-tcctcttcatccc
ctgtgac-3′. To normalize the results, the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
sometimes hSDHAwere used (GAPDH, forward 5′-cgctctc
tgctcctcctgtt-3′, reverse 5′-ccatggtgtctgagcgatgt-3′; SDHA,
forward 5′-tgggaacaagagggcatctg-3′, reverse 5′-ccaccactg
catcaaattcatg-3′). Furthermore, qPCR analysis was per-
formed to validate RNAseq data obtained from SH-SY5Y
cells silenced against luciferase (control), TDP-43 and
DAZAP1. The gene-specific PCR primer pairs used are
as follows: ELAVL3, forward 5′-cctcaaattacagacgaagacca
-3′, reverse 5′-gctgacgtacaggttagcatc-3′; NOVA2 forward
5′-aaggcgaatacttcctgaaggt-3′, reverse 5′-tactaggcatacccgct
ctgt-3′; RELN forward 5′-ttggaggttccagtgctttc-3′, reverse
5′-aaactgaggttggttgtggg-3′; STX3 forward 5′-tcggcagaccttc
ggattc-3′, reverse 5′-tcctcatcggttgtctttttgc-3′; CELF5 for-
ward 5′-aaactcttcgtgggccagat-3′, reverse 5′-ggcacagtaggtg
aggaagg-3′; ACHE forward 5′-agaaagcgtcttccggttct-3′, re-
verse 5′-tacgagccctcatccttcac-3′; TNF forward 5′-cctctctct
aatcagccctctg-3′, reverse 5′-gaggacctgggagtagatgag-3′; TN-
FRSF9 forward 5′-ttggatggaaagtctgtgcttg-3′, reverse 5′-a
ggagatgatctgcggagagt-3′; ICAM1 forward 5′-ggccggccagctt
atacac-3′, reverse 5′-tagacacttgagctcgggca-3′; YPEL4 for-
ward 5′-cggagatctctggagcagac-3′, reverse 5′-gtgtttcagggca
ggagaag-3′;. Real-time PCRs were performed on a Min-
iOpticon real-time PCR and on a CFX96 real-time sys-
tems (Bio-Rad, Hercules, CA, USA). The expression lev-
els were determined using the 2−CT method (Schmittgen
and Livak, 2008). The mean of relative expression levels ±
standard deviation of three independent experiments are
reported. Statistical significance was calculated using un-
paired t-test (indicated as ** for P ≤ 0.01 and as * for P
≤ 0.05).
Flp-In HEK293 cell line expressing TDP-43 aggregates and
RNA silencing of DAZAP1, hnRNP Q and hnRNP R
Flp-In HEK293 cells (Invitrogen) with inducible siRNA re-
sistant FLAG-tagged wild-type TDP-43 (75 × 104) were
seeded in 6-well plates in 1.5 ml of culture medium con-
taining serum and antibiotics. A total of 4 l of 40 M
siRNA against DAZAP1 (Sigma), hnRNP Q (Sigma) and
hnRNPR (Sigma) was diluted in 90 l of Opti-MEM (Life
Technologies) and 6 l of HiPerFect Transfection Reagent
(Qiagen) was added to the diluted siRNA. A siRNA against
fire-fly luciferase (Sigma) was used as a control. The same
procedure of RNA silencing was repeated the day after (sec-
ond silencing) and the third day the cells were seeded in
a new 6-well plates containing microscope slides treated
with 0.1 mg/ml Poly-L-Lysine (Sigma) (for immunofluo-
rescence analysis) and silencing was repeated against each
hnRNPs for the last time (third silencing). After 24 h the
culture medium was changed and the TDP-43 12XQ/N ag-
gregation was induced by addition of 1 g/ml tetracycline
(Sigma). After 48 h the cells were prepared for immunoflu-
orescence analysis or western blot analysis.
Immunofluorescence analysis of Flp-In HEK293 cell line ex-
pressing TDP-43 aggregates
Flp-In HEK293 cells with inducible siRNA resistant
FLAG-tagged wild-type TDP-43 were plated and treated
as described above. For immunofluorescence analysis the
cells were washed three times with PBS, fixed in 3.2%
paraformaldehyde in PBS for 1 h at room temperature and
permeabilized by using 0.3% Triton in PBS for 5 min on
ice. Cells were then blocked with 2% BSA/PBS for 20 min
at room temperature and immunolabeled with 1:200 rab-
bit polyclonal antibody anti-TDP-43 (ProteinTech Group)
and 1:200mouse monoclonal antibody anti-FLAG (Sigma)
overnight at 4◦C. The day after the cells were washed three
times with PBS, incubated with 1:500 anti-mouse Alex-
aFluor 594 (Invitrogen) and 1:500 anti-rabbit AlexaFluor
488 (Invitrogen) for 1 h at room temperature and cover-
slipped with Vectashield-DAPI mounting medium (Vector
Laboratories, Burlingame, CA, USA). Each slide was ana-
lyzed using Nikon Ti-E confocal microscope with a 60× oil
objective and a pinhole size of 1.2 AU.
RESULTS
Suppression of hnRNPs expression canmodify the neurotoxic
phenotypes induced by TBPH overexpression in Drosophila
eyes
To identify physiological partners of TDP-43 function
among the hnRNP family members, we analyzed first
how many human hnRNP proteins presented orthologs in
Drosophila. We focused attention on 12 human hnRNPs
having a counterpart conserved in the fly with a significant
level of confidence (Table 1) as calculated using the DRSC
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Integrative Ortholog Prediction Tool (DIOPT, http://www.
flyrnai.org/diopt) (46). In order to determine which of these
genes were able to modulate TDP-43 activity in vivo, we
completed a systematic gene suppression screening by cross-
ing flies overexpressing, specifically in eye compartment, the
TDP-43 ortholog in Drosophila (TBPH), with a collection
of transgenic lines carrying RNAi sequences against these
12 evolutionary conserved hnRNP proteins (Table 1). In
this study we included Hrp38/hnRNP A1 previously in-
vestigated (32) as a reference for this experiment. Thus, for
the hnRNPs screening, 23 independents RNAi strains were
crossed against GMR-Gal4 flies expressing TBPH in their
eyes (Figure 1A–M and Table 2). Moreover, to evaluate the
specificity of the genetic modifications, the RNAi lines were
alike crossed against GMR-Gal4 flies without expressing
TBPH in the genetic background (Figure 1A’–M’ and Table
2).
TBPH transgene expression (Figure 1A), if compared
toGreenFluorescent Proteins (GFP) expression alone (Fig-
ure 1A’), induced high eye degeneration with loss of pig-
mentation, neuronal death with presence of black spot and
ommatidial fusion, in coincidence with previous studies
(35,47). Interestingly, we found that only few silenced genes
(CG30122, Bl and Sqd) enhanced the neurodegenerative
phenotypes induced by TBPH gain-of-function (Table 2).
In fact, the disorganization of the retinal structures with
significant reduction in the organ size and the presence of
extensive necrotic areas were observed in these three cases
(Figure 1B–D and N). On the contrary, using 19 RNAi
lines 9 genes were able to ameliorate (mildly or strongly) the
structural defects in the external organization of the retinas
and prevent the necrotic degeneration of the photorecep-
tors due to TBPH overexpression (Table 2). In particular,
we were able to find a group of strong suppressors (Hrb27c,
CG42458, Glo, Syncrip/Syp, and Hrp38) whose silencing
rescued almost completely the TBPH-gain-of-function phe-
notype (Figure 1I-M and N) and a group of mild suppres-
sors (Hrb87F, Sm, Heph and Rump) that rescued only par-
tially the TBPH-overexpression-dependent phenotype (Fig-
ure 1E–H and N). Interestingly, we also observed that the
expression of the majority of these genetic modifiers alone
in the Drosophila eyes did not produce apparent defects in
the organization of these tissues, indicating that these genes
were capable to rather specifically modulate TBPH function
in vivo (Figure 1B’–M’ and Table 2).
Interference of hnRNPs activity in TBPH loss-of-function
background dramatically modifies flies locomotor abilities
In a previous work, we demonstrated that the hnRNP
protein Hrp38 was able to enhance the neurodegenerative
phenotype induced by the reduction of TBPH activity in
Drosophila neurons (Romano et al., (32)). Therefore, to
complete the genetic analysis described above and further
explore whether others hnRNPs presented similar pheno-
typic interactions with TBPH in central nervous system,
we generated hypomorphic alleles in this locus. To this
aim, RNAi against TBPH with the pan-neuronal driver
Elav-Gal4 in TBPH heterozygous backgrounds (Elav-Gal4,
tbph23/+; UAS-TBPHRNAi, UAS-Dicer-2) was induced in
flies also expressing the Dicer-2 enzyme (to potentiate gene
silencing efficiency)(Figure 2A-B light grey columns). This
model was previously used successfully and presents lo-
comotive defects in specific climbing assays (Romano et
al., (32)). In addition to establish if TBPH and hnRNPs
were functionally related in the context of metabolic path-
ways, we induced pan-neuronal suppression of hnRNP
proteins alone (Elav-Gal4/UAS-hnRNPRNAi, Figure 2A-B
dark grey columns). Interestingly, we found that the ELAV-
driven silencing of CG42458, Sqd, Rump and CG30122 did
not affect climbing abilities of wild-type background, con-
trol, flies (Figure 2A, dark grey column, and Table 3) sub-
stantially confirming what reported after silencing these
genes in the eye compartment (Figure 1). On the con-
trary, the neuronal silencing of CG42458, Sqd, Rump and
CG30122 in TBPH reduced background (TBPH hypomor-
phic allele) produced a strong enhancement in the climbing
phenotypes (Figure 2A, light grey columns). The suppres-
sion of a second group of hnRNPs (Hrb87F, Glo, Heph, Bl
and Sm) provoked significantly locomotion impairment in
flies, thus overlapping even alone the neurological defects
triggered by the TBPH loss-of-function (Figure 2B and Ta-
ble 3). In addition the silencing of Syp and Hrb27c caused
respectively the complete paralysis and lethality in wild-
type as well as in Elav-Gal4, tbph 23/+; UAS-TBPHRNAi/+
flies (see Table 3). Thus, the silencing ofHrb87F,Glo,Heph,
Bl, Sm, Syp, and Hrb27c in neurons, produced already
climbing defects by their own, making difficult to estab-
lish whether the genetic interactions that we observed in
TBPH hypomorphic backgrounds were due to direct gene
dose effects (Figure 2B, Table 3). In this respect, it is also
important to note that silencing of Syncrip/hnRNP R/Q,
Hrb27c/DAZAP1 and Hrp38/hnRNP A1 did not alter
TBPH expression levels directly as determined by Western
blot (Supplementary Figure S1).
The human orthologs of hnRNPs Hrb27c (DAZAP1) and
Syncrip/Syp (hnRNP Q and R) can contribute to regulate
TDP43-controlledmRNA splicing and gene expression events
The results obtained in the fly model suggested that differ-
ent hnRNPs might be directly and differentially involved
in the molecular regulation of TBPH/TDP-43 activity. We
decided to concentrate on the action of DAZAP1 and hn-
RNP Q/R because these proteins had an extremely pro-
nounced negative effect when knocked out in combination
with TDP-43 (Table 3) but, at the same time, seemed to be
protective in the gain-of-function expression model (Figure
1I, L and Table 2).
Therefore, in order to determine the influence of these
hnRNPs on TDP-43-regulated events, we tested their func-
tions in a series of pre-mRNA splicing processes known to
be consistently altered by TDP-43 depletion (the efficiency
of hnRNP depletion in the SH-SY-5Y cell line used for this
experiment is reported in Supplementary Figure S2). Thus,
the analyzed events were the splicing of SKAR/POLDIP3
exon 3 (48); TNIK exon 15 (14); STAG2 exon 30b (49); and
MADD exon 31 (49).
As shown in Figure 3A–D, the removal of TDP-43 caused
a drop in the inclusion of POLDIP3 exon 3 (Figure 3A), an
increase in TNIK exon 15 inclusion (Figure 3B), an increase
in STAG2 exon 30b inclusion (Figure 3C) and loss of exon
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Table 1. Selected human hnRNPs with their corresponding fly orthologs
Human gene Fly gene % identity (protein) % similarity (protein) ID RNAi
hnRNPA1 Hrp38 48 63 31303 BSC
hnRNP A3 Hrb87F/CG12749 50 63 100732 KK
hnRNP C -/CG42458 30 47 47828 GD
108072 KK
hnRNP D Sqd/CG16901 41 58 32395 GD
hnRNP F/H Glo/CG6946 28 40 27752 GD
110653 KK
hnRNP I (PTBP1) Heph/CG31000 54 66 33735 GD
110749 KK
hnRNP K HnRNP-K/CG13425 35 45 2912 GD
105271 KK
hnRNP L Sm/CG9218 35 49 28117 GD
108351 KK
44658 GD
hnRNPM Rump/CG9373 28 42 44659 GD
1000001KK
33011 GD
hnRNP Q/R Syncrip/CG17838 44 56 33012 GD
110542 KK
hnRNP U -/CG30122 25 40 106984 KK
16040 GD
DAZAP1 Hrb27c/CG10377 35 47 16041 GD
101555KK
The % identity and % similarity for each ortholog protein are shown as reported by the DRSC Integrative Ortholog Prediction Tool (DIOPT, http:
//www.flyrnai.org/diopt). The used fly transgenic lines carrying RNA interference sequences against these 12 evolutionary conserved hnRNP proteins are
also indicated. All RNAis belong to VDRCStock Center (GD andKK libraries) except for hnRNPA1/Hrp38RNAi (#31303) obtained fromBloomington
Stock Center (BSC).
Table 2. Summary of the functional genetic screening silencing hnRNPs in Drosophila eyes
hnRNP RNAi
Human gene Fly gene symbol ID RNAi TBPH GOF Wild-type
Enhancers
hnRNP U -/CG30122 106984 KK ** ns
2912 GD *** ns
hnRNP K Bl/CG13425 105271 KK ns ns
hnRNP D Sqd/CG16901 32395 GD *** ns
Mild Suppressors
44658 GD *** ns
hnRNPM Rump/CG9373 44659 GD *** ns
1000001 KK ns ns
hnRNP I Heph/CG31000 33735 GD *** ns
110749KK *** ns
hnRNP L Sm/CG9218 28117 GD *** ns
108351 KK *** ns
hnRNP A3 Hrb87F/CG12749 100732 KK *** mp
Strong Suppressors
16040 GD *** ns
DAZAP1 Hrb27c/CG10377 16041 GD *** ns
101555 KK *** ns
hnRNP C -/CG42458 47828 GD *** ns
108072 KK *** ns
hnRNP F/H Glo/CG6946 27752 GD *** ns
110653 KK *** ns
33011 GD *** ns
hnRNP R/Q Syp/CG17838 33012 GD *** ns
110542 KK *** mp
hnRNP A1 Hrp38/CG9883 31303BSC *** ns
Results obtained after the RNAi silencing of 12 genes in eyes (GMR-Gal4 driver) of TBPH gain-of-function flies (TBPHGOF) or in eyes of wild-type flies.
The TBPH GOF column collected the results of phenotypic interactions between hnRNPs silenced in TBPH GOF background, describing the hnRNP
RNAis as enhancers, strong suppressors or mild suppressors of the TBPH phenotype. Legend of symbols in table: (***) P-value < 0.001; (**) P-value <
0.01. The wild-type column collected the results of hnRNPs silencing in wild-type background; (ns) indicated that no significant phenotype modification
was revealed; (mp) indicated the presence of a mild rough phenotype.
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Figure 1. RNAi-mediated disruption of hnRNP candidate genes in Drosophila eyes. (A–M) RNAi-mediated knockdown of hnRNPs alters phenotype
of TBPH gain-of-function eyes. Compared the control fly expressing TBPH (A) GMR-Gal4, TBPH/GFP with the following genotypes (B) GMR-Gal4,
TBPH /CG30122RNAi, (C) GMR-Gal4, TBPH;Bl RNAi, (D) GMR-Gal4, TBPH/SqdRNAi, described as enhancers of TBPH phenotype; (E) GMR-Gal4,
TBPH;RumpRNAi, (F) GMR-Gal4, TBPH/HephRNAi, (G) GMR-Gal4, TBPH; Sm RNAi, (H) GMR-Gal4, TBPH/Hrb87FRNAi described as mild sup-
pressors; (I) GMR-Gal4, TBPH; Hrb27c RNAi, (J) GMR-Gal4, TBPH/CG42458 RNAi, (K) GMR-Gal4, TBPH/Glo RNAi, (L) GMR-Gal4, TBPH; Syp
RNAi , (M) GMR-Gal4, TBPH; Hrp38 RNAi indicated as strong suppressors. (A’–M’) RNAi-mediated knockdown of hnRNPs does not alter phenotype of
wild-type eye. Compared the control fly (A’) GMR-Gal4/GFP with the follow genotypes (B’) GMR-Gal4/CG30122RNAi, (C’) GMR-Gal4;BlRNAi, (D’)
GMR-Gal4/SqdRNAi, (E’) GMR-Gal4;RumpRNAi, (F’) GMR-Gal4/HephRNAi, (G’) GMR-Gal4;SmRNAi, (H’) GMR-Gal4; Hrb87F RNAi (I’) GMR-
Gal4; Hrb27c RNAi, (J’) GMR-Gal4/CG42458 RNAi, (K’) GMR-Gal4/GloRNAi, (L’) GMR-Gal4; SypRNAi , (M’) GMR-Gal4; Hrp38RNAi. (N) Quan-
titative analyses of TBPH eye phenotype degeneration. Data show mean phenotype score ± SEM. ***P < 0.001 calculated by non-parametric analysis
Mann–Whitney U-test.
31 inclusion plus activation of a pseudoexon in the MADD
gene (Figure 3D). Interestingly, removal of DAZAP1, hn-
RNP Q and hnRNP R also had a noticeable and consistent
effect on the recognition of these exons. In particular, re-
moval of DAZAP1 could increase POLDIP3 exon 3 inclu-
sion even above normal inclusion levels (Figure 3A), and
decrease TNIK exon 15 (Figure 3B) and STAG2 (Figure
3C) exon 30b inclusion below normal levels, in a specu-
lar manner with respect to TDP-43. Similarly to DAZAP1,
also silencing of hnRNP Q could decrease TNIK exon 15
inclusion below normal levels (Figure 3B). In the case of
hnRNPR, an effect on splicing could be detected on TNIK
exon 15 inclusion that could also be increased above normal
levels in a manner similar to TDP-43 (Figure 3B). Finally,
DAZAP1, hnRNP Q and R do not seem to affect MADD
splicing profile like TDP-43, which induces exon skipping
and pseudoexon inclusion (Figure 3D).
In parallel to pre-mRNA splicing, another TDP-43 con-
trolled event that can also be tested using this approach is
the effects on gene expression levels of TDP-43 targets pre-
viously published by our laboratory. To this aim, we exam-
ined the levels of MADD and BRD8 expression levels as
these were previously reported to be reduced following the
TDP-43 RNAi (49). TNIK was also added as a control,
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Figure 2. RNAi-mediated disruption of hnRNP candidate genes inDrosophila central nervous system. (A and B) The climbing ability analysis of hnRNPs
silenced flies in wild-type background (Elav-Gal4; UAS-Dicer-2) are depicted in dark gray and in TBPH hypomorphic alleles (Elav-Gal4, tbph23/+;
UAS-TBPHRNAi, UAS-Dicer-2) are depicted in light gray. Additional W1118 control is reported in white. ns = not significant, **P < 0.01, ***P < 0.001
calculated by one-way ANOVA. Error bars SEM.
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Figure 3. Effects of DAZAP1 and hnRNP Q/R depletion on TDP-43 controlled events. Differentially treated SH-SY-5Y cells were used to validate the
effects of various hnRNPs on TDP-43 controlled genes. RT-PCR analysis was performed for the following splicing events: POLDIP3/SKAR exon 3 (A),
TNIK exon 15 (B), STAG2 exon 30b (C) andMADD exon 31 (D). The agarose gel was loaded with the following samples: control siRNALuciferase trans-
fected cells (lane 1, siLuc), depleted of TDP-43 (lane 2, siTDP-43), depleted of DAZAP1 (lane 3, siDAZAP1), depleted of hnRNP Q (lane 4, sihnRNPQ)
and depleted of hnRNP R (lane 5, sihnRNPR). The identity of the various transcripts is reported on the right. For the MADD gene, the appearance of
a pseudoexon is also reported (Ps.Ex.). *P < 0.05, **P < 0.01, ***P < 0.001 (n = 3), calculated by student’s t-test. The effects of DAZAP1 and hnRNP
Q/R depletion were also tested on gene expression events controlled by TDP-43. Real-time PCR quantification analysis of MADD (E), BRD8 (F) and
TNIK (G) endogenous transcript levels following siRNA transfection in SH-SY-5Y cells from three independent experiments. Each bar reports the mean
± standard deviation of three independent experiments. The single asterisks indicate significant differences (P≤ 0.05) between the indicated measurements.
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Table 3. Functional genetic interactions screening in the Drosophila central nervous system
hnRNP RNAi
Human gene Fly gene symbol ID RNAi TBPH-RNAi enhancers Wild-type
hnRNP C -/CG42458 47828 GD *** ns
108072 KK *** ns
hnRNP D Sqd/CG16901 32395 GD *** ns
44658 GD *** ns
hnRNPM Rump/CG9373 44659 GD *** ns
1000001KK *** ns
hnRNP U -/CG30122 106984 KK *** ns
hnRNP A3 Hrb87F/CG12749 100732 KK *** *
hnRNP F/H Glo/CG6946 27752 GD *** ***
110653 KK *** ***
hnRNP I Heph/CG31000 33735 GD *** ***
110749 KK *** ***
hnRNP K Bl/CG13425 2912 GD *** ***
105271 KK *** ***
hnRNP L Sm/ CG9218 28117 GD *** ***
108351 KK *** ***
33011 GD paralized paralized
hnRNP Q/R Syp/CG17838 33012 GD paralized paralized
110542 KK paralized paralized
16040 GD lethal lethal
DAZAP1 Hrb27c/CG10377 16041 GD lethal lethal
101555KK lethal lethal
The results of climbing assay obtained after the RNAi silencing of 11 hnRNP genes in central nervous system (Elav-Gal4) in TBPH hypomorphic and
wild-type backgrounds. Legend of symbols in table: (***) P-value < 0.001 (*) P-value < 0.05, (ns) not significant. In the case of Syp/hnRNP R/Q and
Hrb27c/DAZAP1 silencing, the climbing abilities were not measured because the flies appeared completely paralyzed or did not born, respectively.
since its splicing levels were affected by most of these hn-
RNPs. As shown in Figure 3E–G, however, in SH-SY-5Y
cells TDP-43 seemed to have a statistically significant effect
only on the expression levels of the MADD gene. None of
the other hnRNPs was able to affect expression indepen-
dently with the only exception of hnRNP Q that downreg-
ulated TNIK expression for a small but statistically signifi-
cant effect.
Rescue of TDP43-controlled mRNA splicing and gene ex-
pression events by DAZAP1 and hnRNP Q and R
Considering these changes, it was then interesting to take
into account whether the effects mediated by the single hn-
RNPs could be used to rescue splicing events disrupted by
the absence of TDP-43. We then proceeded with the re-
moval of DAZAP1, hnRNP Q and hnRNP R in parallel
with TDP-43 silencing, to determine whether and how these
proteins could further affect these splicing events.
As shown in these figures (Figure 4A–D), DAZAP1 re-
moval significantly rescued the inclusion of POLDIP3 exon
3, the skipping of TNIK exon 15 and the skipping of STAG2
exon 30b. With regards to the MADD gene, although re-
moval of DAZAP1 did not significantly rescue exon 31 in-
clusion, it did prevent pseudoexon inclusion with a very
high efficiency. With regards to hnRNP Q, its removal was
effective to rescue exon skipping of TNIK exon 15 but had
no effect in all other cases. Finally, removal of hnRNP R
had no effect to modify the changes induced by TDP-43
knock down in any of these four genes. As shown in Figure
3E–G, it was interesting to note that also for gene expres-
sion profiles the knockout of DAZAP1 could significantly
rescue the gene expression levels of the MADD and BRD8
genes. No effect could be observed, however, for the knock-
out of either hnRNP Q or R.
The results of these rescue experiments are summarized
in Figure 5A and from this figure it is clear that, out of all
these three hnRNPs tested, DAZAP1 is the most consistent
modifier of the tested TDP-43 targets and that can also ef-
fectively rescue the effects of TDP-43 depletion on RNA
splicing and MADD expression.
DAZAP1 does not affect TDP-43 expression but can bind in
vivo to TDP43-controlled mRNAs
Therefore, in order to further characterize the role of these
hnRNPs in terms of TDP-43 expression and targets we first
tested whether these hnRNPs could directly affect TDP-43
expression, especially DAZAP1. However, a western blot
for TDP-43 following the silencing of DAZAP1, hnRNP
Q and hnRNP R showed that TDP-43 expression was not
appreciably affected by silencing of these proteins (Figure
5B). Also of note, TDP-43 silencing was not capable of af-
fecting significantly the expression of DAZAP1 (Figure 5C)
and that of hnRNP Q and R (Supplementary Figure S3A).
We then tested whether silencing of these three factors
could alter the nuclear localization of TDP-43 leaving its
relative expression levels unchanged. However, immunohis-
tochemical analysis DAZAP1, and hnRNP Q and R si-
lenced cells showed that TDP-43 retained its mostly nuclear
localization (Supplementary Figure S3B–E).
Another possible connection between TDP-43 and these
hnRNPs could be represented by their ability to bind di-
rectly TDP-43 and affect its functional properties. This is
certainly a possibility for hnRNP Q, as previous co-IP ex-
periments have shown a direct interaction between this pro-
tein and TDP-43 (18). In parallel, several proteomic studies
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Figure 4. Rescue of TDP-43 controlled pre-mRNA splicing and gene expression events. RT-PCR of SH-SY-5Y cell lines were used to validate the potential
effects of hnRNP depletion on the splicing profile of various TDP-43 controlled genes: POLDIP3/SKAR exon 3 (A), TNIK exon 15 (B), STAG2 exon
30b (C) and MADD exon 31 (D). The agarose gel was loaded with the following samples: control siRNA Luciferase transfected cells (lane 1, siLUC),
depleted of TDP-43 (lane 2, siTDP-43), depleted of TDP-43 and DAZAP1 (lane 3, siTDP-43/siDAZAP1), depleted of TDP-43 and hnRNP Q (lane 4,
siTDP-43/sihnRNPQ), and depleted of TDP-43 and hnRNP R (lane 5, siTDP-43/sihnRNPR). The identity of the various transcripts is reported on
the right. For the MADD gene, the appearance of a pseudoexon is also reported (Ps.Ex.). *P < 0.05, **P < 0.01, ***P < 0.001 (n = 3), calculated by
one-way ANOVA. The effects of DAZAP1 and hnRNP Q/R depletion were also tested on gene expression events controlled by TDP-43. Real-time PCR
quantification analysis of MADD (E), BRD8 (F) and TNIK (G) transcript levels following siRNA transfection in SH-SY5Y cells. Each bar reports the
mean ± standard deviation of three independent experiments. The double and single asterisks indicate significant differences (P ≤ 0.01 and P ≤ 0.05,
respectively) between the indicated measurements.
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Figure 5. DAZAP1 connections with TDP-43 expression and regulated events. (A) schematic diagram reporting the effects of TDP-43, DAZAP-1, hn-
RNP Q and hnRNP R effects of the four TDP43-controlled splicing events in SH-SY-5Y cells. (B) TDP-43 expression levels measured by western blot
following siRNA silencing in SH-SY-5Y cells of DAZAP1, hnRNP Q and hnRNP R. Silencing of TDP-43 is also reported as a control. (C) Effects of
TDP-43 silencing in SH-SY-5Y cells on DAZAP1 protein expression levels in siRNA TDP-43 treated versus untreated cells. (D) Co-immunoprecipitation
experiments using flag-TDP-43 to check for binding to DAZAP1 (upper panel). The presence of hnRNP H1 in the immunoprecipitated sample is used
as a positive control (middle panel). The lower panel shows the levels of flagged and endogenous TDP-43 in the Input and immunprecipitated sample.
(E) RNA immunoprecipitation experiments to control for DAZAP1 binding to the BRD8, TNIK, STAG2, POLDIP3, MADD transcripts and also two
housekeeping genes, GAPDH and SDHA (used as controls).
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on TDP-43 have also confirmed the presence of hnRNP R
in complexes that contain TDP-43 (18,20).
No previous experimental reports, however, have uncov-
ered a possible interaction between TDP-43 and DAZAP1.
In order to address this issue, therefore, we have per-
formed co-immunoprecipitation experiments by transfect-
ing flagged-TDP-43 in HeLa cells and testedthe presence
of DAZAP1 by western blot. The results of this exper-
iment, presented in Figure 5D, show that TDP-43 and
DAZAP1 do not seem to co-IP together (hnRNP H co-
immunoprecipitation with TDP-43 is reported as positive
control of experimental conditions).
It was then decided to test whether DAZAP1 was capa-
ble of binding to the TDP-43 pre-mRNA targets analyzed
in Figures3 and 4. To do this, we performed RNA-IP anal-
ysis by transfecting a flag-DAZAP1 protein in SH-SY-5Y
cells, immunoprecipitating and testing by RT-qPCR of the
binding of this protein to the POLDIP3, TNIK, MADD
and STAG2 transcripts. As shown Figure 5E, all these tran-
scripts were highly enriched (contrary to what was observed
for two control genes, GAPDH and SDHA).
TDP-43 together with DAZAP1 can alter the expression of a
high number of neuronal and synaptic mRNAs in SH-SY5Y
cells
Based on the results of these RNA-IP experiments, we next
sought to identify all the common target genes whose ex-
pression may be co-regulated by TDP-43 and DAZAP1 in
a more neuronal setting. To achieve this, we then performed
RNAsequencing analysis of the human neuroblastoma SH-
SY5Y cell line depleted by TDP-43 or DAZAP1, by RNAi
and compared results.
The putative differentially expressed genes generated by
RNA-Seq following silencing were identified by compar-
ing to a control sample treated with anti-luciferase siRNA
(siLuc) (upregulation cut-off: >1.3; downregulation cut-
off: <0.7-fold change). Using these criteria, among the to-
tal 17147 genes analyzed by RNA-seq for TDP-43, there
were a total of 3533 genes differentially expressed between
siTDP-43 and siLUC treated cells. Of the 3533 differentially
expressed genes, 1173 (33%) genes were downregulated
while 2360 (67%) genes were upregulated (Figure 6A). Con-
versely, forDAZAP1, there were a total of 7571 genes differ-
entially expressed between siDAZAP1 and siLUC treated
cells. Of the 7571 differentially expressed genes, 3244 (43%)
genes were downregulated while 4327 (57%) genes were up-
regulated. The top 100 hits for TDP-43 and their relative
changes in expression levels are reported in Supplementary
Table S1 whilst the top 250 hits for DAZAP1 are reported
in Supplementary Table S2 (with neuronal pathway genes
highlighted).
Most importantly, the RNA-seq analysis identified 489
co-downregulated and 1435 co-upregulated genes in siTDP-
43 and siDAZAP1 treated cells which represent a no-
table target overlap (Figure 6A). According to the DAVID
database (50), many of these genes are involved in brain
metabolism or potentially related with neurodegeneration.
In particular, from this common list of hits, we then se-
lected for qRT-PCR validation ten genes that have been de-
scribed to possess a relation with brain/inflammation, ac-
cording to the GEO functional annotations of the listed
genes (Figure 6B). The fold changes obtained from qRT-
PCR were compared with RNA-seq expression analysis re-
sults (Figure 6C).
Initially, we gave priority to the genes top ranked in the
siTDP-43 RNA-seq data and then looked for the com-
mon targets, potentially related with neurodegeneration,
regulated by DAZAP1. Among the differentially expressed
genes identified, the coregulation was particularly evident
for seven gene, CELF5 (CUGBP, Elav-Like Family Mem-
ber 5), Syntaxin 3 (STX3), Acetylcholinesterase (ACHE)
Tumor necrosis factor (TNF), Tumor necrosis factor recep-
tor superfamily, member 9 (TNFRSF9), Intercellular adhe-
sion molecule 1 (ICAM1) and YPEL4 (yippee like 4) that
were highly upregulated both by TDP-43 and DAZAP1
RNAi (Figure 6B and C). On the other hand, we found
genes such as ELAV like neuron-specific RNA binding pro-
tein 3 (ELAV3) and Neuro-oncological ventral antigen 2
(NOVA2) that were prominently downregulated by TDP-
43 RNAi (and NOVA2 also by DAZAP1 RNAi). Reelin
(RELN), shown to be regulated only by siDAZAP1 in the
RNA-seq analysis, was selected as a ‘neutral’ (for TDP-43
RNAi treatment) and qPCRs confirmed these data.
We searched for enriched Gene Ontology (GO) anno-
tations in the set of genes that were commonly up- or
downregulated by TDP-43 and DAZAP1. To this aim, the
list of significantly TDP-43 and DAZAP1 regulated tran-
scripts were sorted into GO term categories for ‘molecu-
lar function’ and ‘biological process’ by using the UniPro-
tKB Retrieve/ID mapping tool (http://www.uniprot.org/
uploadlists/). Regarding TDP-43, 2269 out of the 3535 sta-
tistically significantly regulated Ensembl identifiers were
successfully mapped to 8481 UniProtKB IDs. Regarding
DAZAP1, 5137 out of the 7571 statistically significantly
regulated Ensembl identifiers were successfully mapped to
19541 UniProtKB IDs.
For both TDP-43 and DAZAP1, the molecular function
of GO terms associated with regulated transcripts include a
large percentage of transcription factor activity, transcrip-
tion factor binding, nucleic acid binding transcription fac-
tor activity, signal transducer activity, transporter activity,
molecular function regulator and receptor activity (Supple-
mentary Figure S4A).
On the other hand, in the biological process category,
similar percentage in genes involved in ‘cellular process’, bi-
ological regulation, single-organism process and ‘metabolic
processes’ groups were notably represented for both siTDP-
43 and siDAZAP1 (Supplementary Figure S4A). It is
also interesting to note that, among the subcategories, the
molecular events most represented were signal transduc-
tion, autophagy, protein folding/unfoding, immune system
process, biological adhesion, locomotion, presynaptic pro-
cess involved in chemical synaptic transmission and behav-
ior (data not shown).
In addition, the statistical significance of the overlap be-
tween the lists of genes regulated by the two splicing factors
was also evaluated (Supplementary Figure S4B). The over-
lap between both the downregulated and upregulated gene
sets was significantly higher than expected for independent
sets of genes (Supplementary Figure S4B).
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Figure 6. Validation of the TDP-43 or DAZAP1 silencing and comparison between RNA-seq and qRT-PCR results. (A) Summary of downregulated
(<0.7× versus siLUC) and upregulated (>1.3× versus siLUC) genes after siTDP-43 or siDAZAP1 treatments. The number of common (between siTDP-
43 and siDAZAP1) downregulated and upregulated genes is also shown. (B) List of genes associated with brain functions (ELAV3, NOVA2, RELN,
STX3, ACHE, YPEL4, CELF5) or inflammation (TNF, TNFRSF9, ICAM1) selected for validation of the RNA-seq analysis. The expression levels of
genes following siTDP-43 or siDAZAP1 treatments versus the control condition (siLUC) is indicated. (C) Validation of RNA-seq by real time PCR of
the ten selected transcripts. The results are represented as relative expression compared with the control (siLUC). (D) Pathways analysis of differentially
expressed genes following TDP-43 and DAZAP1 depletion as determined by PANTHER, DAVID and UniProt analyses.
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As expected, high enrichment scores for both the up- and
downregulated gene sets were found, for clusters related
to neurodegenerative disease and nervous system-related
genes (Supplementary Figure S4C and Table S4). In par-
ticular, a consistent number of genes was also found to be
related with inflammatory responses, supporting a poten-
tially important impact of TDP-43 and DAZAP1 for neu-
roinflammation and motor neuron pathophysiology, as re-
cently reviewed (51).
Finally, another important feature of this analyses was
the observation that a number of transcripts potentially re-
lated with the activity of the cholinergic system have been
found to be altered (Supplementary Table S3). Even taking
in consideration the glutamatergic (and not cholinergic) na-
ture of Drosophila motoneurons, this finding might be par-
ticularly interesting from the point of view of human ALS
disease that is an example of cholinergic neurodegeneration.
Effects of depleting DAZAP1 and hnRNPQ/R in a loss-of-
function model of TDP-43 pathology
In order to further support these results in a more realis-
tic scenario of TDP-43 pathology, we have taken advan-
tage of a new aggregation system that is based on the Tet-
dependent expression in HEK-293 cells of repetitions of
the prion-like, Q/N-repeated sequence at the C-terminus of
TDP-43 (52,53). The advantage of this system over previ-
ous methodologies is principally based on its ability to in-
duce endogenous TDP-43 aggregation in cells without al-
tering the expression levels of the TARDBP gene or intro-
ducing mutations in its sequence. Of interest, the effects of
this induced aggregation have been recently shown to be
comparable to TDP-43 knockdown in SH-SY-5Y cells (54).
Therefore, using this system we have tested whether knock-
down of DAZAP1, hnRNP Q and hnRNP R can affect
the aggregation of endogenous TDP-43. As shown in Fig-
ure 7A, knockdown of these proteins, in fact, cannot reduce
the accumulation of TDP-43 aggregates in the nucleus and
cytoplasm of cells. Nonetheless, Figure 7B shows that re-
moval of DAZAP1 and hnRNP Q can restore the inclusion
of POLDIP3 exon 3 and the skipping of STAG2 exon 30b
which was induced by the formation of the aggregates. As in
the knockdown experiments performed in SH-SY-5Y cells,
hnRNP R had no ability to rescue either effect. In this sys-
tem, the splicing profiles of the TNIK and MADD genes
could not be tested as it occurs differently in HEK293 cells
compared to the SH-SY-5Y cell lines.
Alterations in the expression of hnRNP proteins in ALS pa-
tients
Finally, it was of interest to find existing supporting evi-
dence for these findings in a disease scenario. Therefore,
as a preliminary approach, we explored GEO deposited
levels of transcripts expressed in human cells and/or tis-
sues from ALS and Spinal Muscolar Atrophy (SMA) pa-
tients where TDP-43 levels are modified. As a result, we
found two connected studies (55,56) where global gene ex-
pression profiling in 13 muscle disease groups of ALS pa-
tients showed the simultaneous alteration in themRNA lev-
els of the hnRNPs highlighted by our experiments: TDP-43
(+121%versus controls)DAZAP1 (+118%versus controls),
hnRNP Q/Syncrip (+120% versus controls) and hnRNPR
(+141% versus controls). The observation that alterations
in ALS patients may not simply be limited to TDP-43 but
can eventually also occur in the expression of these hnRNPs
opens the way for further indepth analyses of the global im-
portance of hnRNP variations in ALS disease.
DISCUSSION
In general, all RBPs present in the eukaryotic nucleus
jointly collaborate to regulate all the aspects of an mRNA
life cycle, from transcription to translation (57). How they
achieve this with remarkable accuracy is still the subject
of numerous studies. First, because each of these proteins
generally binds hundreds or thousands of transcripts and
as a result, determining specific versus non-specific inter-
actions is still a challenging question (58). Second, even if
we knew exactly where each hnRNP was binding in the eu-
karyotic transcriptomewe still lack a comprehensive knowl-
edge of the functional properties of each RNA binding pro-
tein. Moreover, both RNA-binding properties and function
can be deeply affected by post-translational modifications
which are very common and can potentially affect pathol-
ogy especially inALS andFTD (59–61). In conclusion, even
for well known hnRNP proteins that have been studied for
several years it is still difficult to predict exactly which tran-
scripts or cellular pathways could be affected by their pres-
ence or absence. Most importantly, it is still very difficult to
predict what kind of influence they may have on each other,
either by affecting their expression/function or binding to
similar sets of targets (62).
For this reason, a better understanding of this issue may
have considerable importance for our understanding of neu-
rodegenerative processes. The working hypothesis is that
differences in expression levels of hnRNP proteins within
a neuron in the presence of the same disease-causing muta-
tion or aberrant aggregation of key RBP proteins identified,
such as TDP-43 and FUS/TLSmay result in profound con-
sequences.
In this work, therefore, we have addressed in a compre-
hensive manner the possible effect of most major nuclear
hnRNP proteins on TDP-43 pathology using well char-
acterized fly models: analyzing both loss-of-function and
gain-of-function scenarios. To do this, we have exploited the
fact that hnRNPs represent a very ‘old’ and conserved class
of proteins. As a result, we have been able to focus our at-
tention on 12 human hnRNPs (Table 1) for which fly strains
expressing shRNA are available.
Depletion of almost all these hnRNPs on a reducedTDP-
43 expression background was observed to generally have
a deleterious effect on the locomotor abilities of flies, al-
though to different extent. This result may not be partic-
ularly surprising, as many of these proteins are already
known to participate in alternative splicing processes that
play a central role in brain development and functioning
(32,63).
As a central conclusion, the picture that emerges from
this study is that the majority of all major hnRNP proteins
have some potential to modify TDP-43 functional conse-
quences both in a loss-of-function and gain-of-function sce-
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Figure 7. Immunofluorescence assay of Flp-InHEK293 FLAG-tagged wild-type TDP-43 cells. (A) Themerged image shows the localization of the endoge-
nous TDP-43 (green) and aggregated (red) TDP43-F4L-12XQ/N after RNA silencing of DAZAP1, hnRNP Q and hnRNP R. A siRNA against fire-fly
Luciferase (Luc) was used as a control. Scale bars: 16 m. (B) RT-PCR of Flp-In HEK293 cell lines expressing TDP-43 aggregates were used to validate
the potential effects of hnRNP depletion on the splicing profile of POLDIP3 exon 3 and STAG2 econ 30b. Western blot analysis of RNA silencing against
DAZAP1, hnRNP Q and hnRNP R. Antibody anti-Tubulin (-Tub) was used as a loading control.
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narios, meaning similarly regulated target genes, metabolic
pathways of sub-cellular mechanisms.
In particular, out of all the tested hnRNPs, we have de-
cided for several reasons to further concentrate our efforts
on three hnRNPs: DAZAP1, hnRNP Q and hnRNP R.
First of all, because they displayed a rather interesting be-
havior with respect to the TDP-43 disease models. In the
loss-of-function scenarios, in fact, knockout of these hn-
RNPs caused paralysis or lethality of flies. In a gain-of-
function scenario, however, they were capable of rescuing
the toxicity induced by TBPH overexpression in the fly eye.
Second, they are less characterized hnRNPs with respect
to hnRNP C and F/H, and might thus represent a novel
research area worthy of exploration. In particular, in the
pre-mRNA processing field no general study has been per-
formed with regards to DAZAP1 targets to this date and
very little on hnRNP Q and R (64).
Most importantly, however, it is interesting to note that
previous studies have identified these proteins as being
important for neuronal development. For example, hn-
RNP R has been reported to localize in presynaptic com-
partments at neuromuscolar endplates and can interact
with SMN protein both in vitro and in vivo (65), where
TDP-43 is known to play important roles (66–68). Simi-
larly, Syncrip/hnRNPQ has been demonstrated to regulate
synaptic transmission signaling at the Drosophila synapse
and regulates the expression of mRNAs for key synaptic
proteins (69,70). On the other hand, although initially iden-
tified as a binding partner of the germ-specific factor DAZ
(71), DAZAP1 has been recently shown to play a very im-
portant role in numerous cell types by regulating mRNA
translation and pre-mRNA splicing process (72–74).
The conclusion of our experiments on these proteins has
confirmed the central role of DAZAP1 as a central mod-
ifier of TDP-43 toxicity that has been previously reported
by Ritson et al. (35). The reason for this activity probably
relies on the fact that both proteins TDP-43 and DAZAP1,
can target a very similar set of transcripts.
The IDmapping of transcripts regulated by these two nu-
clear factors (Supplementary Figure S4) shows a high level
of overlap in the targeted functional categories and suggest
that one of the reasons DAZAP1 can modify TDP-43 ef-
fects on RNA metabolism and its depletion is lethal in flies
could be because both proteins target the same potentially
critical pathways for brain metabolism.
Intriguingly, our RNA sequencing analysis has further
uncovered that most of these transcripts can be impli-
cated with brain functions and potentially with neurode-
generation (Figure 6D and Supplementary Tables S1–4). Of
course, there are still several open questions that will need
to be addressed. First and foremost, the observation that a
majority of genes relating to neurodegeneration were reg-
ulated into the same direction by silencing of TDP-43 and
DAZAP1. Nonetheless, abnormalities in splicing that are
induced by the silencing of TDP-43 in human cells could be
rescued by the silencing of DAZAP1. The most likely pos-
sibility, of course, could be that the transcripts which allow
the rescue of the TDP-43 splicing phenotype by DAZAP1
are within the minority of genes which are differentially reg-
ulated by the two proteins. However, further work will be
required to clarify this issue.
A second issue that also remains to be investigated re-
gards the possible influence of non-coding RNAs (lncR-
NAs) in modulating these hnRNP interactions. It has been
described, in fact, that both TDP-43 and FUS can interact
with several lncRNAs and can regulated both their func-
tions and stability (75). In particular, TDP-43 has been
shown to interact and regulate important lncRNAs such
as gadd7 (76), MALAT1 (77), NEAT1-2 (78), transposable
elements general (79) and two SPA lncRNA involved in
Prader-Willi syndrome (80). How these hnRNPs may help
or hinder TDP-43 in regulating these molecules is some-
thing that will need to be determined.
These future connections imply that connections between
TDP-43 and hnRNP proteins may well go well beyond the
splicing process that has represented the focus of this work.
In a more general context, and in addition to the con-
siderations that relate specifically to TDP-43 functions, the
question that our work has also partially answered regards
the extent at which results obtained in fly overexpression or
knock-down models can be translated to human neuronal
cell lines. This is obviously a very important issue consider-
ing the massive use of flyDrosophilamodels in neurodegen-
eration and the need to eventually ‘translate’ these results
in the human context. In our opinion, our results paint a
rather optimistic view. Of course, differences will always ex-
ist between the two systems, but it is encouraging that, in
our splicing assays, proteins such as DAZAP1 and hnRNP
Q can rescue the disregulation caused by TDP-43 absence
in a manner that is reminiscent of the TDP-43 OE rescue in
the fly eye by Hrp27c and Syncrip. In particular, based on
our RNAseq data, the reason for these similar properties
probably relies in the degree of functional conservation by
these proteins as described in this work.
In the future, the molecular characterization of the co-
regulated transcripts potentially playing amajor role in neu-
rodegeneration and how they might be regulated in differ-
ent brain regions by differing hnRNP expression levels will
hopefully provide us with a better ability to follow disease
onset/progression and might help to pinpoint novel key
therapeutic targets that are still currently lacking.
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